Skip to content
Nosopharm logo — company profile

Nosopharm

Founded 2009 France France 4 employees Debt Financing Total: $4.27M Biotechnology, Pharmaceutical

General Information

Company Name Nosopharm
Founded Year 2009
Location France France
Employees 4
Industries Biotechnology, Pharmaceutical
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Nosopharm. To contact Nosopharm, visit nosopharm.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nosopharm compare?

A PDF of Nosopharm and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nosopharm soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Nosopharm

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. Founded in 2009, it has recently received a €1.00M Debt Financing investment on 12 February 2018, with the investor being Bpifrance. Nosopharm's unique approach to combat AMR through the development of new molecules presents an intriguing investment opportunity in the biotechnology and pharmaceutical industries, making it a potential game-changer in the global fight against antimicrobial resistance.

Business keywords: Antimicrobial Resistance, Drug Discovery, Innovation, Medicinal Mining, Anti-Infectives, Microbial Biodiversity, Antibiotics, Bioactive Secondary Metabolites, Hospital-Acquired Infections, Xenorhabdus, Photorhabdus, AMR, Medical Research, Bacterial Resistance

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing €1.00M 1
Bpifrance
12 Feb 2018
Venture Round €2.40M 3
Auriga Partners, Kreaxi +1
28 Mar 2017
Venture Round €870.00K 3
Auriga Partners, Kreaxi +1
07 Nov 2013

Nosopharm Alternatives & Competitors

View All Alternatives
Nosopharm vs

To save lives or restore health as a leader in safe, rapidly deployable, cost-effective cures for ba...

Acquired
28 employees
Biotechnology, Health Care
Nosopharm vs

Clinical-stage biopharmaceutical company focused on novel antibiotics, antifungals, and treatments f...

1 employees
Biopharma, Biotechnology
Nosopharm vs

Modulating innate immunity to improve cancer therapy outcomes. .

Grant
4 employees
Biotechnology, Pharmaceutical

FAQ About Nosopharm

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medica...
Nosopharm was founded in 2009.
Nosopharm is headquartered in France.
Nosopharm operates in Biotechnology and Pharmaceutical. Its work centres on Antimicrobial Resistance, Drug Discovery, Innovation and Medicinal Mining.
Nosopharm has approximately 4 employees.
Nosopharm has completed 3 funding rounds, raising a total of $4.27M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Nosopharm include Adaptive Phage Therapeutics, Biocidium Biopharmaceuticals, Akthelia Pharmaceuticals, MerLion Pharmaceuticals GmbH, Sealife PHARMA® GMBH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nosopharm and Adaptive Phage Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nosopharm, https://bouncewatch.com/company/nosopharm, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout